Kohnen T, Lwowski C, Hemkeppler E, et al. - The safety and efficacy of femtosecond (fs) laser-assisted in situ keratomileusis (LASIK) combined with accelerated corneal cross-linking (LASIK Xtra) vs conventional fs-LASIK (convLASIK) in high myopic patients were determined via performing a prospective, randomized, fellow-eye controlled clinical trial. At the Department of Ophthalmology, Goethe University, Frankfurt/Germany, treatment was provided to 26 patients with high myopia and/or myopic astigmatism with LASIK Xtra (30 mW/cm², 90 seconds with continuous ultraviolet-A) in 1 eye and convLASIK in the other eye. Outcomes suggest LASIK Xtra as apparently safe, but with no advantages over conventional LASIK. At 12 months, no difference regarding uncorrected distance visual acuity and refractive stability, and no signs of keratectasia were evident in the two groups.